Lainie Martin is an Oncology physician affiliated with Argosy University. OpenAlex indexes 281 publications with 7,521 citations (h-index 41); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
Philadelphia, PA 19104
Telephone
215-615-0063Registry record last updated 29 May 2018.
Clinical trials
- Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
Sponsor: TetraLogic Pharmaceuticals
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Sponsor: Gynecologic Oncology Group
- Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Sponsor: TetraLogic Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- Genmab U.S., Inc.Program year20246 payments$12,377openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.8%Serotonin-3 Receptor Antagonist37.8%Ondansetron Hcl100%Part D≥12 patientsBlood & clotting
32.4%Factor Xa inhibitor32.4%Eliquis100%Part D<11 patientsNervous system
29.7%Phenothiazine29.7%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
- Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients
Research Inst of Fox Chase Can Ctr
FY2014$147,300R01CA151374 - Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients
Research Inst of Fox Chase Can Ctr
FY2013$1R01CA151374 - Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients
Fox Chase Cancer Center
FY2012$426,421R01CA151374
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network
2024 - Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
New England Journal of Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”